Replies to post #105217 on Biotech Values

[AlpineBV_Miller]

IMGN is reporting interim PII data at ESMO in a few weeks in 1st line BC. A PIII is already being run for the 1st line indication. IMGN is also reporting other clinical data at ESMO and ASH so it may have some life in it until the end of the year.

Good points. The ASH data are mostly retreads with a few more patients added. The ESMO data might provide a bump, but the P2 data are so far away I'd expect it to be short-lived.